BioTuesdays

Author - Leonard Zehr

Collegium Pharma

WB starts Collegium Pharma at outperform

William Blair & Co. has initiated coverage of Collegium Pharmaceutical (NASDAQ:COLL) with an “outperform” rating and price target of $35. The stock closed at $19.25 on Thursday. Collegium’s lead product, Xtampza ER...

Novellus

NovellusDx expands board, raises $10-million

Closely-held NovellusDx of Israel has appointed Heiner Dreismann and Dr. Charles Woler to the board. “The appointment of Drs. Dreismann and Woler, both venerated leaders in the biotech and pharma industries, with strong...

Titan Pharmaceuticals Logo

FDA extends Probuphine action date

The FDA has extended its action date to consider approval of a NDA for Probuphine for the maintenance treatment of opioid addiction by the standard period to May 27 from Feb. 27. Following the Psychopharmacologic...

novadaq

Novadaq posts 54% jump in Q4 revenue

Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) has reported revenue of $20-million for the final quarter of 2015, up 54% from $13-million in the year earlier quarter, and up 18% from the third quarter of 2015. Product...

microbix

Microbix sees record sales in fiscal 2016

Microbix Biosystems (TSX:MBX) expects a strong performance over the rest of the fiscal year based on indicated customer demand, leading the company to project record sales for the current fiscal year, ending Sept. 30...

In conversation with Charles Haff

By Len Zehr As a senior research analyst at Craig-Hallum Capital Group, Charles Haff covers medical devices and ancillary healthcare services. Previously, he covered medical devices at Dougherty & Company and was a...

Avivagen

Avivagen begins trial of OxC-beta with UNAHCO

Avivagen (TSX-V:VIV) has started a trial with UNAHCO at the University of the Philippines Los Banos to measure the benefits of OxC-beta livestock as a feed additive for broiler poultry. Trial design reflects a...